Agomab Therapeutics NV
corporate_fare Company Profile
Agomab Therapeutics NV (NASDAQ:AGMB) is a publicly traded company in the Life Sciences sector. Wiseek monitors AGMB SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- FDA Greenlights Agomab's Phase 2b Crohn's Disease Trial Design
- Agomab Finalizes Phase 2b Study Design for Ontunisertib in Fibrostenosing Crohn's Disease, FDA Aligned
- Agomab Secures Cash Runway to 2029 with $208M IPO, Confirms Key Clinical Milestones for H2 2026
- Agomab Therapeutics Advances Two Lead Candidates to Phase 2, Extends Cash Runway to H1 2029
- Agomab Secures U.S. Patent for Key IPF Drug AGMB-447, Protecting IP Through 2041
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for AGMB, detected from its recent SEC filings · based on capital-structure filings through 2026-03-05.
Initial Public Offering Priced · Pipeline Funding Secured
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
AGMB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.